Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more
Mereo BioPharma Group plc (MAH0) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.157x
Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has a cash flow conversion efficiency ratio of -0.157x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.31 Million) by net assets (€46.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mereo BioPharma Group plc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Mereo BioPharma Group plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mereo BioPharma Group plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mereo BioPharma Group plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northern Ocean Ltd
PINK:NTNOF
|
0.073x |
|
Financeira Alfa S.A. - Crédito Financiamento e Investimentos
SA:CRIV3
|
2.577x |
|
Pacific Petroleum Transportation JSC
VN:PVP
|
N/A |
|
OXFORD METRICS LS-0025
F:RNI
|
N/A |
|
Cheng Fwa Industrial Ltd
TWO:5426
|
0.026x |
|
1895 of Wisconsin Inc Bancorp
NASDAQ:BCOW
|
0.003x |
|
Emvision Medical Devices Ltd
AU:EMV
|
-0.323x |
|
River Valley Community Bancorp
PINK:RVCB
|
N/A |
Annual Cash Flow Conversion Efficiency for Mereo BioPharma Group plc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Mereo BioPharma Group plc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €60.97 Million | €-32.83 Million | -0.539x | -28.79% |
| 2023-12-31 | €50.54 Million | €-21.13 Million | -0.418x | +33.36% |
| 2022-12-31 | €61.87 Million | €-38.82 Million | -0.627x | -953.98% |
| 2021-12-31 | €88.00 Million | €-5.24 Million | -0.060x | -103.14% |
| 2020-12-31 | €-14.97 Million | €-28.34 Million | 1.893x | +265.92% |
| 2019-12-31 | €40.26 Million | €-45.93 Million | -1.141x | -61.59% |
| 2018-12-31 | €32.77 Million | €-23.14 Million | -0.706x | -37.23% |
| 2017-12-31 | €62.48 Million | €-32.15 Million | -0.515x | -37.48% |
| 2016-12-31 | €79.26 Million | €-29.66 Million | -0.374x | -- |